StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.10−0.05 (-4.35%)

Close on Nov 18, 2026Market cap $115.90MP/E –Yield –

ProQR Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ProQR Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -€42.85M. For fiscal 2025 it was -€43.45M. The highest annual figure on record is -€27.00M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€43.45M–
FY2024Dec 31, 2024-€30.47M–
FY2023Dec 31, 2023-€31.86M–
FY2022Dec 31, 2022-€65.16M–
FY2021Dec 31, 2021-€57.21M–
FY2020Dec 31, 2020-€42.37M–
FY2019Dec 31, 2019-€57.45M–
FY2018Dec 31, 2018-€36.29M–
FY2017Dec 31, 2017-€40.50M–
FY2016Dec 31, 2016-€39.57M–
FY2015Dec 31, 2015-€27.00M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€8.82M–
Q1 FY2026Mar 31, 2026-€13.65M–
Q4 FY2025Dec 31, 2025-€9.10M–
Q3 FY2025Sep 30, 2025-€11.28M–
Q2 FY2025Jun 30, 2025-€12.25M–
Q1 FY2025Mar 31, 2025-€10.82M–
Q4 FY2024Dec 31, 2024-€10.08M–
Q3 FY2024Sep 30, 2024-€8.72M–
Q2 FY2024Jun 30, 2024-€3.60M–
Q1 FY2024Mar 31, 2024-€8.08M–
Q4 FY2023Dec 31, 2023-€6.27M–
Q3 FY2023Sep 30, 2023-€7.39M–
Q2 FY2023Jun 30, 2023-€8.81M–
Q1 FY2023Mar 31, 2023-€9.39M–
Q4 FY2022Dec 31, 2022-€12.46M–
Q3 FY2022Sep 30, 2022-€19.82M–
Q2 FY2022Jun 30, 2022-€15.83M–
Q1 FY2022Mar 31, 2022-€17.04M–
Q4 FY2021Dec 31, 2021-€17.33M–
Q3 FY2021Sep 30, 2021-€14.56M–
Q2 FY2021Jun 30, 2021-€13.20M–
Q1 FY2021Mar 31, 2021-€12.10M–
Q4 FY2020Dec 31, 2020-€11.67M–
Q3 FY2020Sep 30, 2020-€10.86M–
Q2 FY2020Jun 30, 2020-€3.36M–
Q1 FY2020Mar 31, 2020-€16.48M–
Q4 FY2019Dec 31, 2019-€17.42M–
Q3 FY2019Sep 30, 2019-€13.45M–
Q2 FY2019Jun 30, 2019-€11.84M–
Q1 FY2019Mar 31, 2019-€14.74M–
Q4 FY2018Dec 31, 2018-€12.85M–
Q3 FY2018Sep 30, 2018-€5.92M–
Q2 FY2018Jun 30, 2018-€7.67M–
Q2 FY2017Jun 30, 2017-€10.18M–

More ProQR Therapeutics figures

See a number that looks wrong?